SGLT2 medicine for high-risk people after sudden worsening heart failure
Treatments studied
Part of Heart & circulation clinical trials.
This Phase 3 trial tests whether starting an SGLT2 inhibitor early in the hospital can improve outcomes for people at high risk after acute (sudden) heart failure. If you qualify, you would be randomized to receive the study medicine or standard care, started within 12 hours of admission.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 20 years old and consent to take part (or have a Mini-Cog check if age 90+)
- Be hospitalized with sudden heart failure that needs IV loop diuretic “fluid medicine”
- Have shortness of breath at rest or with slight activity, plus at least 2 signs of fluid buildup (or meeting BNP/NT-proBNP blood test thresholds)
- Have evidence of higher risk, such as weaker kidney function, higher-dose home furosemide use, or low urine output right after IV furosemide
- Not have been on an SGLT2 inhibitor in the last 3 months
- Not have conditions that make SGLT2 use unsafe, such as very low blood pressure, risk of severe blood sugar complications, or planned dialysis
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a medicine (SGLT2 inhibitor) given to people with high blood pressure and early signs of heart stress can help prevent heart failure. You may join if your blood pressure is controlled but tests show your heart is beginning to struggle.
This study tests whether a medicine called an SGLT2 inhibitor (which lowers blood sugar and helps the kidneys) can improve outcomes for people with acute heart failure and kidney problems. Participation involves taking the study drug or a placebo for a short time.
This trial tests whether adding two heart medicines together (finerenone and an SGLT2 inhibitor) helps people who are in the hospital for heart failure recover better. It may be an option for you if you are currently hospitalized and your heart stress markers are high.
This trial studies whether two medicines—an SGLT2 inhibitor and potassium nitrate—can improve symptoms and heart function in people with heart failure with preserved ejection fraction (HFpEF). It focuses on people who still have signs of “stiff” or high filling pressure in the heart despite a normal-ish ejection fraction.
This trial tests a new medication called enavogliflozin (an SGLT2 inhibitor) to see if it helps people with a specific type of heart failure where the heart pumps normally but is stiff. You may be able to join if you have stable heart failure, are not on another SGLT2 inhibitor, and have good kidney function.
This trial tests if dapagliflozin, a medication usually used for diabetes, can help people with acute heart failure recover heart function. If you are in the hospital for heart failure, this study will check if the drug improves how your heart squeezes.
Hear when a new Acute Heart Failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.